Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ASTI vs ABVC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Captures Overall Composite Edge (47.4 HOLD vs 44.5 HOLD), While ASTI Leads 3–2 on Growth & Valuation Pillars

ABVC Overall Winner 6-Pillar Tally: ASTI 3 – 2 ABVC (1 Tie) Matrix Metrics: ASTI 3 – 6 ABVC

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) captures the overall head-to-head institutional edge over Ascent Solar Technologies, Inc. (ASTI) on higher Unified Composite conviction (47.4/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–3 (led by Growth & Scale, Profitability & Quality), while ASTI wins 3–2 across the 6-pillar growth and valuation breakdown. ASTI trades at $0.77 (14.4x Forward P/E, -2759.6% operating margin) versus ABVC at $0.87 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ABVC earns the overall head-to-head edge with a stronger Unified Composite Score (47.4/100 HOLD vs. ASTI 44.5/100 HOLD) and 1.24β · 44% Vol risk profile, whereas ASTI leads top-line expansion (+514.3% YoY revenue growth, 0.96x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ASTI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.4); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ASTI vs ABVC
ASTI NASDAQ
Ascent Solar Technologies, Inc. Common Stock
Semiconductors & Related Devices
$0.77
-9.55% 1D
Market Cap $12.6M
TTM Revenue $338,161
Forward P/E 14.4x
Beta / 30D Vol 4.37β · 123% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 59.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -24.6%), weak momentum, RSI 20
RSI-14: 20.4 · SMA20: $1.40 · SMA50: $2.00
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.87
-1.56% 1D
Market Cap $23.9M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.24β · 44% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $0.98 · SMA50: $1.01

6-Pillar Scorecard Institutional Category Breakdown (ASTI 3 – 2 ABVC)

Columns: Metric · ASTI · ABVC
1. Valuation Multiples ASTI
Forward P/E 14.4x N/M
Trailing P/E 14.4x N/M
PEG Ratio 0.96x N/M
EV / Revenue N/M 29.9x
2. Growth & Scale ABVC
Revenue Growth (YoY) +514.3% +104.5%
Earnings Growth (YoY) -90.2% +0.0%
TTM Revenue (USD) $338,161 $797,916
Market Cap $12.6M $23.9M
3. Profitability & Quality ABVC
Gross Margin N/A 100.0%
Operating Margin -2759.6% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -111.3% -52.7%
4. Balance Sheet & Cash Flow ASTI
Cash Generation (TTM) -$7.4M -$5.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $13M Net Cash $0.50 Book/Sh · -52.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ASTI
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 104.4% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Solar Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ASTI (3) vs ABVC (6)
Institutional Metric ASTI ABVC Criterion Row Edge
Market Capitalization
Scale
$12.6M $23.9M Larger Scale ABVC
Trailing P/E Ratio
Valuation
14.4x N/M Lower Multiple ASTI
Forward P/E Ratio
Valuation
14.4x N/M Lower Multiple ASTI
Revenue Growth (YoY)
Growth
+514.3% +104.5% Higher Growth ASTI
Operating Margin (TTM)
Profitability
-2759.6% 0.0% Higher Margin ABVC
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-111.3% -52.7% Higher ROE ABVC
52-Week Range Position
Momentum
0% ($1–$10) 7% ($1–$3) Stronger Trend ABVC
Beta / 30D Volatility
Risk Regime
4.37β · 123% Vol 1.24β · 44% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 47.4 / 100 (HOLD) Higher Composite ABVC
Trailing 12M Revenue (USD)
Operating Scale
$338,161 $797,916 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.96x PEG · N/M EV/Rev N/M PEG · 29.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.4M ($13M Net Cash) -$5.8M EBITDA ($0.50 Book/Sh · -52.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVC +39.1 pp
ASTI: -56.38% · ABVC: -17.28%
3M Horizon ABVC +77.65 pp
ASTI: -74.52% · ABVC: +3.13%
6M Horizon ABVC +61.59 pp
ASTI: -85.6% · ABVC: -24.01%
1Y Horizon ASTI +15.8 pp
ASTI: -52.35% · ABVC: -68.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ASTI vs ABVC. Trailing 12-month operating profitability (ASTI -2759.6% vs ABVC 0.0%) and valuation multiples (ASTI 14.4x vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ASTI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$338,161
Gross MarginN/A
Op. Margin-2759.6%
ROE / Fwd P/E-111.3% · 14.4x
ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ASTI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 104.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ASTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ASTI Moat Profile Cyclical / Execution-Driven Positioning
Solar Operator
Competes within the Solar value chain with $12.6M market capitalization and -2759.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ASTI vs ABVC Key Questions & Quantitative Answers

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) captures the overall head-to-head institutional edge over Ascent Solar Technologies, Inc. (ASTI) on higher Unified Composite conviction (47.4/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–3 (led by Growth & Scale, Profitability & Quality), while ASTI wins 3–2 across the 6-pillar growth and valuation breakdown. ASTI trades at $0.77 (14.4x Forward P/E, -2759.6% operating margin) versus ABVC at $0.87 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ABVC earns the overall head-to-head edge with a stronger Unified Composite Score (47.4/100 HOLD vs. ASTI 44.5/100 HOLD) and 1.24β · 44% Vol risk profile, whereas ASTI leads top-line expansion (+514.3% YoY revenue growth, 0.96x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ASTI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.4); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVC leads the Growth & Scale pillar: ASTI posts +514.3% YoY revenue growth and -90.2% YoY earnings growth on $338,161 TTM revenue (N/A gross margin, -2759.6% operating margin), compared with ABVC at +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, ASTI generates $338,161 in USD-normalized revenue versus $797,916 for ABVC. In operating R&D and SG&A reinvestment, ASTI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVC.

ASTI screens cheaper on headline valuation multiples. ASTI trades at 14.4x Forward P/E, 14.4x Trailing P/E, 0.96x PEG, and N/M EV/Revenue (unreported FCF margin), whereas ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ASTI (-111.3% ROE) versus ABVC (-52.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ASTI carries 104.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.37β · 123% Vol realized risk). By comparison, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.